This was not observed in our population, in which only 9% of the T2D patients were under treatment with SGLT-2 inhibitors, and may be explained by the recency of such recommendations, and by the presence of renal function below the label threshold. Here, SLC5A2 is linked to type 2 diabetes mellitus.